By Doug Macron

Start-up Rana Therapeutics this week announced that it has raised $20.7 million in a Series A round of financing, which the company hopes will allow it to advance a lead drug candidate into investigational new drug application-enabling studies around the end of this year.

According to Rana President and CEO Art Krieg, the 12-employee company has obtained very promising data with its core gene-activation technology in both in vitro and in vivo studies.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: mtDNA analysis give glimpse into decline of Neanderthals in Europe, and more.

The University of Arizona's Raina Maier writes that an understanding of the Earth's microbiome is needed.

The proposed Canadian budget emphasizes partnerships with industry, Nature News reports.

An Australian study of personalized medicine has run into problems as it recruits patients.